“A PROSPECTIVE STUDY OF ANTITUBERCULAR DRUGS ON LIVER FUNCTION TESTS IN NEWLY DIAGNOSED TUBERCULOSIS PATIENTS”

Main Article Content

Ganesh Prasad Sagar
Kumar Vivek Anand
Onkar Nath Tiwari

Keywords

Antitubercular Drugs; Newly Diagnosed Tuberculosis; Liver Function Test; Hepatotox

Abstract

Background: This is a prospective study on tuberculosis and liver illness patients , it is necessary to determine the factors that put patients at risk for developing anti-tuberculosis drug-induced hepatotoxicity (anti-TB-DIH). In this study, both the prevalence of anti-TB-DIH and the factors that contribute to its development were studied. As a consequence of this, the purpose of the present study was to explore the abnormal liver function test in patients who were being treated for tuberculosis.


Aims and Objectives: (i) To investigation of liver dysfunction in antitubercular patients. (ii) To protect the liver from chemotherapy drug side effects through early detection. (iii) To understand drug-induced liver toxicity risk factors.


Materials and Methods: This is a prospective study of one hundred patients who were treated at the Department of Pulmonary Medicine and the Department of Biochemistry at the Sarojini Naidu Medical College, Agra. Results: Patients varying in age from 15 to 30 years comprised 21 (21%) of the study, 31–50 years comprised 31% of the study, 51–70 years comprised 38% of the study, and 71–80 years comprised 10% of the study, with 68 (68%) males and 32 (32%) females. When compared to the levels that were present before therapy, the levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) exhibited a substantial increase after 2 months of treatment. A comparison of the patient’s levels of AST, ALT, ALP, and gamma-glutamyl transpeptidase (GGT) before treatment and after treatment for 6 months demonstrated a considerable rise in all of these enzymes’ activities.


Conclusion: In this study the majority of patients suffer hepatotoxicity within the first 14 days of beginning antituberculosis therapy (ATT) medication, it is imperative that the liver function of patients be monitored in the initial days in which treatment with ATT is being initiated.

Abstract 0 | Pdf Downloads 0

References

World Health Organization. Global TB Report. Geneva: World Health Organization; 2022. Available from: https://www.who. int/tb/publications/global_report/en [Last accessed on 2023 May 28].
2. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002;166:916-9.
2-. Krishnaswamy K. Nutritional status and hepatotoxicity. Trop Geogr Med 1991;3:156-60.
4. Wu S, Xia Y, Lv X, Zhang Y, Tang S, Yang Z, et al. Effect of scheduled monitoring of liver function during anti-tuberculosis treatment in a retrospective cohort in China. BMC Public Health 2012;12:454.
5. Singh J, Garg PK, Tandon RK. Hepatotoxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy. J Clin Gastroenterol 1996;22:211-4.
6. Døssing M, Wilcke JT, Askgaard DS, Nybo B. Liver injury during antituberculosis treatment: An 11-year study. Tuber Lung Dis 1996;77:335-40.
7. Narwadiya SC, Dhumne UL, Tumane PM, Meshram VG. Assessment of liver enzymes level in the serum of tuberculosis patients during directlyobserved short term chemotherapy (DOTS). Biomed Pharmacol J 2008;1:449-52.
8. Chang TE, Huang YS, Su WJ, Perng CL, Huang YH, Hou MC. The role of regular liver function monitoring in antituberculosis drug-induced liver injury. J Chin Med Assoc 2019;82:535-40.
9-Vagvala SH, O'Connor SD. Imaging of abnormal liver function tests. Clin Liver Dis (Hoboken). 2018 May;11(5):128-134. [PMC free article] [PubMed]
10. Sailendra V, Poojitha T, Ravicharan A. Study of anti-tubercular drugs on liver function in newly diagnosed pulmonary tuberculosis patients. IOSR J Dent Med Sci (IOSR-JDMS) 2018;17:30-4.
11. Molla Y, Wubetu M, Dessie B. Anti-tuberculosis drug induced hepatotoxicity and associated factors among tuberculosis patients at selected hospitals, Ethiopia. Hepat Med 2021;13:1-8
12. Ezhilarasan D. Antitubercular drugs induced liver injury: An updated insight into molecular mechanisms. Drug Metab Rev 2023;55:239-53.